ArticleMolecular biomedicine2026
Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Psoriatic arthritis (PsA) lacks reliable biomarkers to support early diagnosis and disease stratification. This study aimed to identify protein signatures associated with PsA and develop a clinically relevant model integrating molecular and clinical features. We conducted a cross-sectional study including 143 patients with PsA and 101 controls across three cohorts. The exploratory cohort included 77 patients with PsA and 50 symptomatic controls without inflammatory disease. Two independent cohorts were used for external validation: validation cohort 1 comprised PsA patients receiving conventional DMARDs, and validation cohort 2 included PsA patients receiving biological treatment. Proteomic profiling of 384 inflammation-related proteins was performed in PBMCs using Olink technology. Machine learning-based approaches were applied to identify and optimize a diagnostic biomarker model integrating proteomic and clinical variables. Functional in vitro assays were conducted to evaluate the mechanistic regulation of biomarker-associated proteins. Sixty-eight proteins were significantly dysregulated in PsA, highlighting activation of immune-inflammatory pathways. Several proteins correlated with arthritis severity, psoriasis burden, and CRP. A five-parameter diagnostic model (ESR, plaque psoriasis, LILRB4, ADGRE2, SIGLEC10) showed excellent discrimination across all three cohorts. The upregulation of LILRB4, ADGRE2, and SIGLEC10 in PBMCs exposed to PsA serum supported their mechanistic relevance. Distinct proteomic signatures differentiated early from established PsA, revealing molecular patterns linked to disease progression. This study identifies a potential protein signature associated with PsA and provides a validated diagnostic model with high accuracy. These findings advance molecularly guided diagnosis and highlight biomarkers with both mechanistic and translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.